Data Foundry

Drug recalls 2023

fentaNYL 2 mcg/mL and bupivacaine 0 — Class II drug recall D-1069-2023

Terminated recall by Central Admixture Pharmacy Services Inc, reported 2023-08-09, distributed nationwide. Lack of assurance of sterility: Lack of validation data for sanitization cycles

Recall numberD-1069-2023
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmCentral Admixture Pharmacy Services Inc, San Diego, CA, United States
Recall initiated2023-07-17
Classified2023-08-03
Reported by FDA2023-08-09
Terminated2025-03-21
DistributedNationwide (US)
Quantity295 bags
Reason classessterility
NDC71286-2081-01
Lot numbers17-271814, 17-271960, 17-272252, 17-272272, 17-272454, 17-272640, 17-272716
Expiration dates2023-08-06, 2023-08-08, 2023-08-13, 2023-08-14, 2023-08-16, 2023-08-20, 2023-08-21

Product

fentaNYL 2 mcg/mL and bupivacaine 0.0625% PF in 0.9% sodium chloride, Total Volume = 250 mL, Total fentaNYL 500 mcg/250 mL, 250 mL bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2081-1

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1069-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.